| Document |
Document Title |
|
WO/2013/067578 |
Heterocyclic compounds that modulate C3a receptors and their use in the treatment or prevention of inflammatory diseases, infectious diseases, cancers, metabolic disorders, obesity, type 2 diabetes, metabolic syndrome and associated card...
|
|
WO/2013/070910 |
Described herein are compositions and methods for treating or preventing a sexually transmitted infection in a subject
|
|
WO/2013/066134 |
The present invention relates to cinnamyl-rhodanine derivative compounds or pharmaceutically acceptable salts thereof, and to a pharmaceutical composition comprising the compounds as active ingredients. More particularly, cinnamyl-rhodan...
|
|
WO/2013/064518 |
A compound of formula (I), wherein R1 to R4 are, for example, each hydrogen, R5 is, for example, an unsubstituted aromatic 6-membered heterocycle; R6 is, for example,hydrogen; R7 is,for example, hydrogen, cyano, hydroxyl, formyl, C1-C4-a...
|
|
WO/2013/065725 |
The present invention relates to a phthalamide derivative represented by general formula (I) or a salt thereof. [In the formula, X1 represents a halogen atom or the like; X2 represents a halogen atom or the like; m represents 0, 1, 2 or ...
|
|
WO/2013/065463 |
The present invention is a method for producing a phenyl-substituted heterocyclic derivative (1), which comprises a step wherein a heteroaromatic compound represented by general formula (2) is reacted with a phenol derivative represented...
|
|
WO/2013/064543 |
The invention provides compounds that are useful in the treatment of hepatitis C virus (HCV) infections. The compounds have the formula (1): or a salt, N-oxide, tautomer or stereoisomer thereof, wherein A is CH or N; E is CH or N; R1 is ...
|
|
WO/2013/062027 |
The invention according to the present application provides a therapeutic or prophylactic agent for diseases including mood disorders, anxiety disorders, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eatin...
|
|
WO/2013/059928 |
Compounds of Formula I are disclosed: wherein A, R1, R2, R3, R4A, R4B, R5, R6 and R7 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors. The compounds and their pharmaceutically...
|
|
WO/2013/055771 |
Tdp1 inhibitors of Formula (I) and methods of using those inhibitors to treat cancer are provided in this disclosure. R1 is hydrogen or lower alkyl and G is a substituted phenyl or optionally substituted heteroaryl group. The disclosed T...
|
|
WO/2013/054940 |
The purpose of the present invention is to provide a novel therapeutic agent and preventive agent for demyelinating disease. The present invention is a therapeutic agent and a preventive agent for demyelinating disease that contain as an...
|
|
WO/2013/053034 |
The present invention relates to 3-acridinyl-methyl-thiazolidine-2,4-dione-derived compounds, also denominated thiazacridines, and to the related processes for chemically synthesizing same, and also to the therapeutic use thereof for tre...
|
|
WO/2013/044371 |
A compound according to Formula IA and IB, reversibly convertible under photochromic and electrochromic conditions between a ring-open isomer A and a ring-closed isomer B is provided. For substitutent groups, Z is N, O or S; each R1 is i...
|
|
WO/2013/046781 |
The invention pertains to a compound shown by the formula (I) and a process for the manufacture thereof. (In the formula, Ax represents an organic group having 2-30 carbon atoms having at least one aromatic ring of an aromatic hydrocarbo...
|
|
WO/2013/041526 |
The invention relates to alkylamidothiazoles of general formula (I), wherein R 1 = -Cl-C24 alkyl (linear and branched), -C1-C24 alkenyl (linear and branched), -C1-C8 cycloalkyl, -C1-C8 cycloalkyl-alkylhydroxy, -C1-C24 alkylhydroxy (linea...
|
|
WO/2013/041537 |
The invention relates to heterocyclocarbonylaminothiazoles of general formula (I), wherein R 1 = -morpholino, -piperidin-1-yl, -piperazin-1-yl, -((4-alkyl)-piperazin-1-yl), -pyrrolidinyl, -(1H-pyrrol-1-yl), -azetidin-1-yl, -azepan-1-yl, ...
|
|
WO/2013/041535 |
The invention relates to aromatic amidothiazoles of the general formula, in which R 1 = -C3-C24 aryl (optionally monosubstituted or polysubstituted with -OH, -F, -Cl, -Br, -I, -OMe, -NH2, -CN, acetyl, polysubstituted with hydroxy, wherei...
|
|
WO/2013/043001 |
The present invention provides a phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The phenylimide-contai...
|
|
WO/2013/043002 |
The present invention provides an imide-containing benzothiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The imide-containing benzot...
|
|
WO/2013/041468 |
Disclosed are compounds with the formula (I), where R1 and R2 are as disclosed herein, which are eIF4E inhibitors useful in the treatment of cancers. Also disclosed are compositions comprising the compounds, as well as methods of treatin...
|
|
WO/2013/039187 |
[Problem] To provide a compound useful as a renal disease preventive and/or therapeutic agent. [Solution] The inventors of the present invention investigated compounds having a trypsin inhibitory activity, verified that a guanidinobenzoi...
|
|
WO/2013/037717 |
The present invention provides fungicidal 4-substituted-3-{phenyl[(heterocyclylmethoxy)imino]methyl}-1
,2,4-oxadiazol-5(4H)-one derivatives of formula (I) wherein A represents a pyridyl or thiazole group and X1, Y1 to Y5 represent indepe...
|
|
WO/2013/035827 |
The purpose of the present invention is to provide: a novel compound which is represented by formula (I') and has ACC2 inhibitory activity; and a medicinal composition which contains the compound. (In the formula, R1 represents a substit...
|
|
WO/2013/035047 |
The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form(I) a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provid...
|
|
WO/2013/035650 |
The present invention relates to a specific thiazolium salt used for producing an ∝-hydroxy ketone compound, and a method for producing an ∝-hydroxy ketone compound by carrying out a coupling reaction of an aldehyde compound in the p...
|
|
WO/2013/033515 |
The present invention provides compounds and methods for assaying redox state of metabolically active cells and methods for assaying enzyme activity and/or metabolite level by coupling to redox defining co-factor NAD(P)/NAD(P)H measurement.
|
|
WO/2013/029648 |
A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein: - R' is H or F or trifluoromethyl; - R'' is OH or O-alkyl; - R''' is H or F or trifluoromethyl or phenyl or pyridyl; - R'''' is methylene or acy...
|
|
WO/2013/029555 |
Provided are lavendustin A derivatives, a preparation method and use thereof. The compounds are shown by the structure of formula (I), wherein R is alkyl, ether group, carbonyl, p-tolyl, five-membered heterocyclic group, five-membered su...
|
|
WO/2013/031694 |
A compound represented by general formula or a salt thereof is useful as an antifungal agent. (In the formula, R1 and R2 may be the same or different and each represents a halogen atom, a cyano group, a nitro group, an optionally substit...
|
|
WO/2013/026806 |
The present invention relates to novel thiazolo[5,4-ƒ]quinazoline compounds and methods that are useful in the amelioration, treatment or control of Down's syndrome or early Alzheimer's disease or in the amelioration, treatment or contr...
|
|
WO/2013/027694 |
The purpose of the present invention is to provide a near infrared light-emitting compound which has an ability to highly specifically binding to Aβ, a high permeability through the blood-brain barrier, an ability to quickly disappear f...
|
|
WO/2013/027770 |
[Problem] To provide a modified firefly luciferin and a modified firefly luciferin analogue that retain the property of luminescing by the action of luciferase in a firefly bioluminescent system, in particular, to provide novel luminesce...
|
|
WO/2013/025733 |
Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one ...
|
|
WO/2013/023109 |
The inventions disclosed and described herein relate to new and efficient generic methods for making a wide variety of compounds having HAr - Z - Har tricyclic cores (II) from intermediates (I), wherein HAr is an optionally substituted f...
|
|
WO/2013/021971 |
[Problem] To provide an organic photoelectric conversion element whereby conversion efficiency is increased by morphology reformation in a power generation layer, and whereby short-circuit current (Jsc) attenuation when emitting light is...
|
|
WO/2013/022047 |
The present invention provides a compound which has an inhibitory activity on lysine-specific demethylase 1 and is useful as a medicinal agent such as a prophylactic or therapeutic agent for cancer and central nervous system diseases. Th...
|
|
WO/2013/023107 |
The inventions disclosed and described herein relate to new and efficient generic methods for making a wide variety of compounds having HAr - Z - Har tricyclic cores, wherein HAr is an optionally substituted five or six membered heteroar...
|
|
WO/2013/023106 |
The inventions disclosed and described herein relate to new and efficient generic methods for making a wide variety of compounds having HAr - Z - Har tricyclic cores, wherein HAr is an optionally substituted five or six membered heteroar...
|
|
WO/2013/023108 |
The inventions disclosed and described herein relate to new and efficient generic methods for making a wide variety of compounds having HAr - Z - Har tricyclic cores, wherein HAr is an optionally substituted five or six membered heteroar...
|
|
WO/2013/017654 |
Compounds of formula (I) or a pharmaceutically acceptable ester, amide, carbamate or salt thereof, including a salt of such an ester, amide or carbamate in which R1 to R9 have meanings as defined in the Specification, are useful as estro...
|
|
WO/2013/018095 |
The present invention is directed to compounds such as: formula wherein linker is independently selected from the group consisting of -S-, -S-S-, -S-(CH2)n-, -NH-, -NH-(CH2)n-, -0-, -S02-, arylene, heteroarylene; Rl is selected from the ...
|
|
WO/2013/018735 |
The purpose of the present invention is to provide a novel compound which has an anti-fungal activity on pathogenic fungi including fungi belonging to the genus Candida, the genus Aspergillus and the genus Trichophyton and is useful as a...
|
|
WO/2013/019978 |
Embodiments of probes for selectively detecting compounds having a thiol group and an amino group, e.g., cysteine and/or homocysteine, are disclosed, along with methods and kits for detecting the compounds in neutral media with the probe...
|
|
WO/2013/016727 |
Novel cysteine prodrugs and their use in the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of the Central Nervous System (CNS), including but not limited to schizophrenia, drug craving, ...
|
|
WO/2013/014205 |
The present invention relates to compounds of the formulae (Ia) and (Ib), wherein G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the pro...
|
|
WO/2013/014204 |
The present invention relates to compounds of the formula I, wherein Ht, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cat...
|
|
WO/2013/014204 |
The present invention relates to compounds of the formula I, wherein Ht, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cat...
|
|
WO/2013/013113 |
This invention relates to methods for treating bone disease associated with osteoclast activation using HDAC6 selective inhibitors, e.g., small molecule inhibitors such as reverse amide compounds.
|
|
WO/2013/010218 |
Inhibitors are provided for inhibiting the activity of clathrin. In particular, binding site(s) on the clathrin terminal doman (TD) for binding inhibitors have been identified. The binding sites are defined by amino acid(s) in the group ...
|
|
WO/2013/010218 |
Inhibitors are provided for inhibiting the activity of clathrin. In particular, binding site(s) on the clathrin terminal doman (TD) for binding inhibitors have been identified. The binding sites are defined by amino acid(s) in the group ...
|
